| Description |
Publish Date |
LINKS |
Important safety information on vaccines in Ukraine
|
10/10/2018
|
|
Important safety information on Seretide in Ukraine
|
10/10/2018
|
|
Important safety information on Dolutegravir in Ukraine
|
10/10/2018
|
|
| Important safety information on Belimumab in Ukraine |
02/04/2019 |
|
| Important safety information on Abacavir: Hypersensitivity reaction - educational slide deck |
15/02/2024 |
|
| Important safety information on Volibris in Ukraine (Information for Healthcare Professionals) |
14/07/2023 |
|
| Important safety information on Volibris in Ukraine (Patient booklet) |
14/07/2023 |
|
| Important safety information on Volibris in Ukraine (Memo for female patients taking Volibris) |
14/07/2023 |
|
| Important safety information on Volibris in Ukraine (Information for male partners of women taking Volibris) |
14/07/2023 |
|
| Reminder information for patients taking Volibris (Reminder card) |
14/07/2023 |
|
| Important safety information on Cephalosporins in Ukraine (Safety Notification_Cephalosporins and risk of seizure) |
01/03/2023 |
|
Important safety information on Cephalosporins in Ukraine (Safety Notification_Cephalosporins and risk of neurotoxicity) |
07/03/2023 |
|
Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Ukraine |
09/09/2023 |
|
| Important safety information on Lamotrigine containing products in Ukraine |
09/09/2023 |
|
| Important safety information on Paroxetine containing products in Ukraine |
27-10-2023 |
|
| Important safety information on Cefuroxime sodium containing products in Ukraine |
30-10-2023 |
|
| Important safety information on Dolutegravir containing products in Ukraine (Safety Notification_Korean label update for Dolutegravir containing products) |
31-10-2023 |
|
| Important safety information on Topical Corticosteroids containing products in Ukraine |
20-11-2023 |
|
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Ukraine (Initial Safety Notification Engerix-B and Myelitis_November 2023) |
20-11-2023 |
|
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Ukraine (Updated Safety Notification Engerix-B and Myelitis_December 2023) |
27-12-2023 |
|
Important safety information on Amoxicillin/clavulanic acid containing products - MedSafe communication regarding labelling updates |
18/12/2023 |
|
Important safety information on Zanamivir containing products - Precautions for prescribing and administering flu medications (zanamivir) |
22/12/2023 |
|
Important safety information on Paroxetine containing products - Modifications of the information of medicines authorized by national procedure that contain Paroxetine |
22/12/2023 |
|
Important safety information on Acyclovir containing products - Safety Notification EMA-PRAC: The MAH has been requested to provide cumulative reviews of the below-mentioned issues in the next PBRER to be submitted for acyclovir |
02/01/2024 |
|
Important safety information on Dolutegravir containing products - Dolutegravir and sexual dysfunction |
11/01/2024 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine (Updated Safety Notification Engerix-B and Myelitis_January 2024_1st upd) |
08/01/2024 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine (Updated Safety Notification Engerix-B and Myelitis_January 2024_2nd upd) |
26/01/2024 |
|
Important safety information on Lamotrigine containing products - Safety Signal received from Swissmedic: Lamictal - Interaction with hormone replacement therapies (HRT) |
18/03/2024 |
|
Important safety information on Lamotrigine containing products - El Salvador safety alert-LAMICTAL 5 mg, LAMICTAL 25 mg, LAMICTAL 50 MG, LAMICTAL 100 MG |
18/03/2024 |
|
Important safety information on Valaciclovir containing products - Adaptation of the medicinal product information for Valaciclovir containing products |
18/03/2024 |
|
Important safety information on Umeclidinium bromide/vilanterol trifenatate containing products - Minutes from French HA (ANSM) meeting / signal for umeclidinium bromide/vilanterol trifenatate (ANORO) |
20/03/2024 |
|
Important safety information on Lamotrigine containing products - Safety Signal received from Swissmedic: Lamictal - Interaction with hormone replacement therapies (HRT), updated information, April 2024 |
05/04/2024 |
|
Important safety information on Amoxicillin/clavulanic acid containing products - Drug-induced gastroenteritis syndrome |
10/04/2024 |
|
Important safety information on Mepolizumab containing products - PBRER final assessment report (fAR) for EU PBRER 24 March 2023 to 23 September 2023 |
15/04/2024 |
|
Important safety information on Acyclovir containing products - ACYCLOVIR/VALACYCLOVIR – RISK OF DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) |
17/04/2024 |
|
Important safety information on Paroxetine containing products - Modifications of the information of medicines authorized by national procedure that contain: PAROXETINE, updated information, April 2024 |
19/04/2024 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine - Updated Safety Notification Engerix-B and Myelitis_May 2024 |
07/05/2024 |
|
